CRBP

MKT CAP:$126M

Corbus Pharmaceuticals Holdings, Inc.

Market Cap

$126M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$10.22+$2.35 (+29.86%)

Apr 23, 2026

Company Details

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid re...

CEO

Yuval Cohen

IPO Date

Oct 27, 2014

Website

www.corbuspharma.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$79M

EPS (Diluted)

-$5.98

Free Cash Flow

-$64M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Mar 9, 2026

$0EPS -$5.90

Q4 2025

Mar 9, 2026

$0EPS -$1.25

Q3 2025

Nov 12, 2025

$0EPS -$1.90

Q2 2025

Aug 5, 2025

$0EPS -$1.44

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$368.5K	-$9M
Q2 22	$0	-$370.4K	-$7M
Q3 22	$0	-$374.8K	-$8M
Q4 22	$0	$0	-$11M
Q1 23	$0	$0	-$17M
Q2 23	$0	$0	-$8M
Q3 23	$0	$0	-$9M
Q4 23	$0	-$148.0K	-$10M
Q1 24	$0	$0	-$10M
Q2 24	$0	-$200.0K	-$11M
Q3 24	$0	$0	-$16M
Q4 24	$0	-$146.0K	-$13M
Q1 25	$0	-$16M	-$20M
Q2 25	$0	-$100.0K	-$19M
Q3 25	$0	$0	-$24M
Q4 25	$0	-$49.0K	-$22M

Valuation

Quarter	P/S	P/E
Q1 22	262.1x	—
Q2 22	343.2x	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$11M	-$11M
Q2 22	-$12M	-$12M
Q3 22	-$7M	-$7M
Q4 22	-$7M	-$7M
Q1 23	-$15M	-$15M
Q2 23	-$8M	-$8M
Q3 23	-$7M	-$7M
Q4 23	-$6M	-$6M
Q1 24	-$8M	-$8M
Q2 24	-$9M	-$9M
Q3 24	-$14M	-$14M
Q4 24	-$11M	-$11M
Q1 25	-$16M	-$16M
Q2 25	-$17M	-$17M
Q3 25	-$16M	-$16M
Q4 25	-$16M	-$16M

Capital Expenditures

Quarter	CapEx
Q1 22	$13.4K
Q2 22	$0
Q3 22	$0
Q4 22	$5
Q1 23	$0
Q2 23	$5
Q3 23	$0
Q4 23	$0
Q1 24	$2
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$7.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-100.0%	-47.0%
Q2 22	-100.0%	-56.4%
Q3 22	-100.0%	-41.4%
Q4 22	—	+8.0%
Q1 23	—	+103.1%
Q2 23	—	+11.6%
Q3 23	—	+16.0%
Q4 23	—	-6.4%
Q1 24	—	-44.4%
Q2 24	—	+34.2%
Q3 24	—	+63.4%
Q4 24	—	+24.8%
Q1 25	—	+105.5%
Q2 25	—	+74.3%
Q3 25	—	+57.5%
Q4 25	—	+74.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	—
Q2 22	$2M	—
Q3 22	$1M	—
Q4 22	$1M	—
Q1 23	$1M	—
Q2 23	$0	—
Q3 23	$821.0K	—
Q4 23	$799.2K	—
Q1 24	$0	—
Q2 24	$1M	—
Q3 24	$2M	—
Q4 24	$0	—
Q1 25	$2M	—
Q2 25	$2M	—
Q3 25	$2M	—
Q4 25	$1M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$3M	—	$5M
Q2 22	$2M	—	$4M
Q3 22	$4M	—	$4M
Q4 22	$6M	$5M	—
Q1 23	$13M	$4M	—
Q2 23	$4M	$4M	—
Q3 23	$7M	$3M	—
Q4 23	$7M	—	$3M
Q1 24	$6M	$4M	—
Q2 24	$7M	$4M	—
Q3 24	$11M	$5M	—
Q4 24	$9M	—	$4M
Q1 25	$16M	$4M	—
Q2 25	$15M	$4M	—
Q3 25	$21M	—	$4M
Q4 25	$18M	$7M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$57M	$29M	$86M
Q2 22	$26M	$48M	$73M
Q3 22	$12M	$54M	$66M
Q4 22	$17M	$42M	$59M
Q1 23	$7M	$37M	$44M
Q2 23	$8M	$28M	$37M
Q3 23	$11M	$17M	$29M
Q4 23	$14M	$7M	$21M
Q1 24	$14M	$106M	$120M
Q2 24	$24M	$123M	$147M
Q3 24	$19M	$140M	$159M
Q4 24	$17M	$132M	$149M
Q1 25	$19M	$114M	$133M
Q2 25	$20M	$97M	$117M
Q3 25	$27M	$77M	$104M
Q4 25	$28M	$135M	$163M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	4M	+0.0%	+7.6%
Q2 22	4M	+0.0%	+7.6%
Q3 22	4M	+0.0%	+0.0%
Q4 22	4M	-0.1%	-0.1%
Q1 23	4M	+0.2%	+0.2%
Q2 23	4M	+2.3%	+2.5%
Q3 23	4M	+3.4%	+5.9%
Q4 23	4M	+0.0%	+6.0%
Q1 24	3M	-36.4%	-32.7%
Q2 24	3M	0.0%	-34.3%
Q3 24	12M	+327.2%	+171.6%
Q4 24	12M	+1.4%	+175.3%
Q1 25	12M	+0.2%	+333.8%
Q2 25	12M	+0.3%	+335.2%
Q3 25	12M	+0.5%	+2.4%
Q4 25	13M	+8.2%	+9.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	41
Q2 22	$0	41
Q3 22	$0	41
Q4 22	$0	33
Q1 23	$0	33
Q2 23	$0	33
Q3 23	$0	33
Q4 23	$0	19
Q1 24	$0	19
Q2 24	$0	19
Q3 24	$0	19
Q4 24	$0	28
Q1 25	$0	28
Q2 25	$0	28
Q3 25	$0	28
Q4 25	$0	200K

Revenue / Employee